Search Bar & Filters
Found 10 Actively Recruiting clinical trials
Actively Recruiting
Researchers are evaluating the safety, effectiveness, best dose, and how the body processes a drug called BNT326 alone and combined with other immunotherapies in people with advanced solid tumors. These tumors are either metastatic, recurrent, or have progressed despite prior treatments. The study includes multiple specific tumor types and is divided into two parts, each enrolling participants independently to assess BNT326 alone or with other drugs like pumitamig. Participants in Part 1 receive BNT326 alone in different groups based on their tumor type, including cutaneous melanoma, non-small cell lung cancer, rare melanomas, cervical cancer, and other solid tumors. Part 2 studies BNT326 alone or combined with pumitamig for various cancers such as melanoma, breast cancer, gastric cancer, colorectal cancer, and cervical cancer. Some groups involve random assignment to different dose levels, while others do not. Treatments are given via intravenous infusion or oral administration depending on the drug. Participants undergo a screening period followed by treatment lasting up to 24 months or until disease progression, consent withdrawal, study end, or unacceptable side effects. After treatment, there are safety and efficacy follow-up periods, plus long-term survival tracking, with total involvement lasting about 38 months for Part 1 and 48 months for Part 2. Researchers monitor side effects, tumor response, survival, and drug levels in the blood to assess safety and activity of the treatments.
Actively Recruiting
Researchers are evaluating the effectiveness and safety of the drug rilvegostomig compared with pembrolizumab as a first-line treatment for patients with metastatic non-small cell lung cancer mNSCLC whose tumors have high levels of PD-L1. This Phase III, randomized, double-blind, global study focuses on patients with mNSCLC who meet specific genetic and health criteria to understand how these treatments perform in this group. Participants receive either rilvegostomig or pembrolizumab, both given intravenously on the first day of each 21-day treatment cycle. The study has two groups one receiving rilvegostomig and the other pembrolizumab, with treatments continuing as part of their first-line cancer care. The trial monitors these treatments over several years to assess long-term outcomes. During the study, participants will have regular assessments including scans to measure tumor response, evaluations of physical function, quality of life questionnaires, and tests to monitor drug levels and immune responses. The main outcomes tracked are overall survival and progression-free survival over approximately five years. Safety and patient-reported symptoms are also closely monitored throughout the study period.
Actively Recruiting
Researchers are evaluating elecoglipron, a drug administered orally once daily, for adults with type 2 diabetes mellitus T2DM who also have impaired kidney function and are receiving background treatment with dapagliflozin 10 mg, a sodium-glucose cotransporter 2 inhibitor SGLT2i. This phase III, randomized, double-blind study aims to assess the efficacy, safety, and tolerability of elecoglipron compared with placebo in this population, who are also on other glucose-lowering medications. Participants will be randomly assigned to receive either elecoglipron at one of two dose levels or a placebo, all given orally once daily alongside their background dapagliflozin treatment. The study uses a parallel-group design and will continue for 40 weeks, during which participants treatment adherence and response will be monitored closely. Throughout the study, participants will undergo regular assessments including measurements of hemoglobin A1c HbA1c from baseline to week 40, body weight, blood pressure, and fasting plasma glucose. Researchers will also track the time to initiation of any rescue medication and monitor for any hypoglycemic events. Safety and tolerability will be continuously evaluated during this period to understand the overall impact of elecoglipron compared to placebo.
Actively Recruiting
Researchers are studying the safety, tolerability, and effectiveness of DS-3939a, alone or combined with other cancer treatments, in people with solid tumors, including locally advanced unresectable or metastatic non-squamous non-small cell lung cancer NSCLC. The study is an open-label trial with two independent substudies focusing on different patient groups and treatment combinations, including immunotherapy and chemotherapy. It aims to better understand how these treatments work in advanced lung cancer cases. Participants receive intravenous infusions of DS-3939a every three weeks, either alone or combined with pembrolizumab, carboplatin, pemetrexed, or DS-1103a, depending on their subgroup. The study has two parts for each substudy dose escalation Part 1 to find the recommended dose, followed by dose expansion Part 2 where participants are randomized to different treatment groups. Treatments continue until disease progression or other reasons for stopping treatment. During the study, participants will have regular assessments including imaging scans to monitor tumor response based on RECIST v1.1 criteria, safety evaluations, and blood tests to measure drug levels. Researchers will track side effects, tumor shrinkage, disease control, and survival over several years. The study also includes long-term monitoring of drug concentrations and immune responses. Participants can expect frequent visits for treatments and evaluations throughout the study period.
Actively Recruiting
Researchers are evaluating zipalertinib, a new EGFR tyrosine kinase inhibitor TKI, compared to a placebo in people with early stage non-small cell lung cancer NSCLC who have uncommon EGFR mutations and have had their tumors completely surgically removed. The study focuses on participants with specific uncommon EGFR mutations, including exon 20 insertions and others in exons 18-21, aiming to understand the treatments impact on disease-free survival after surgery. Participants are randomly assigned to receive either zipalertinib or a matching placebo, both taken orally twice daily. Treatment continues until certain criteria for stopping are met. An independent committee will monitor safety during the study. The study plans to include about 360 participants and will last up to 5 years for measuring outcomes. Throughout the trial, participants will be closely monitored with brain imaging before starting treatment to ensure no brain metastases. Researchers will assess disease-free survival as their main outcome over up to 5 years, along with overall survival and quality of life measures. Safety will be evaluated through tracking adverse events, lab tests, vital signs, heart function via ECG and scans, and quality of life questionnaires. Participants will have regular visits for treatment and assessment over the study period.
Actively Recruiting
Researchers are evaluating the efficacy and safety of pegozafermin in adults aged 18 to 75 years who have biopsy-confirmed and clinically confirmed compensated cirrhosis caused by metabolic dysfunction-associated steatohepatitis MASH. This phase 3 study aims to compare pegozafermin against a matched placebo to better understand its effects on liver fibrosis and disease progression in this population. Participants will receive either pegozafermin or a placebo through subcutaneous injections. The study is randomized and quadruple-blinded, ensuring neither participants nor researchers know which treatment is given. Treatment effects will be observed over a period of up to 5 years, with primary outcomes measured at 24 months, including fibrosis regression and time to disease progression based on specified clinical events. Throughout the study, participants will undergo regular assessments, including liver function tests like ALT and AST, enhanced liver fibrosis scores, FibroScan elastography, and evaluations for portal hypertension and other liver-related complications. Safety monitoring will track adverse events during the treatment and follow-up period. The trial spans several years, allowing long-term observation of treatment outcomes and participant health.
Actively Recruiting
Researchers are evaluating treatments for people with advanced non-small cell lung cancer NSCLC that has spread or cannot be controlled by current therapies. This study focuses on patients whose cancer cells have specific changes called HER2 mutations, which cause abnormal cell growth. The main goal is to compare the effectiveness and safety of a new drug called sevabertinib against the standard treatment for this condition. Participants will be randomly assigned to one of two groups one group will take sevabertinib tablets twice daily, and the other will receive the current standard treatment, which includes pembrolizumab combined with platinum-based chemotherapy given by vein infusion every 21 days. Those on standard treatment may switch to sevabertinib if their cancer worsens. Treatment continues as long as participants benefit and do not have severe side effects. During the study, participants will undergo scans like CT, PET, MRI, or X-rays to monitor their cancer. Health assessments include blood and urine tests, heart checks using electrocardiograms and echocardiograms, pregnancy tests when needed, and evaluations of how participants feel and any medical problems they experience. The main outcome measured is how long participants live without their cancer progressing, with other outcomes including overall survival and response rates. The study lasts up to about 4 years, with ongoing monitoring for safety and patient well-being.
Actively Recruiting
Researchers are studying belzutifan monotherapy to assess its effectiveness and safety in treating advanced pheochromocytomaparaganglioma PPGL, pancreatic neuroendocrine tumors pNET, von Hippel-Lindau VHL disease-associated tumors, advanced wild-type gastrointestinal stromal tumor wt GIST, and other advanced solid tumors with Hypoxia Inducible Factor-2 alpha HIF-2 genetic alterations. The primary goal is to measure the objective response rate ORR using standardized criteria through independent review. Participants will receive belzutifan orally at a dose of 120 mg once daily. This treatment continues until the disease progresses or the participant decides to stop. The study is designed as a single-group phase 2 trial focusing solely on belzutifan monotherapy without a comparison group. During the study, participants will be regularly monitored for treatment response, duration and time to response, disease control, progression-free survival, overall survival, and any adverse events. These assessments will be conducted for up to approximately 5.5 years. Safety and efficacy are closely observed throughout this period to understand the treatment impact over time.
Actively Recruiting
Researchers are evaluating the combination of brenetafusp IMC-F106C plus nivolumab compared to standard nivolumab regimens in people with previously untreated advanced melanoma who are HLA-A*0201-positive. This phase 3, randomized, controlled study aims to understand how these treatments perform in this specific group. The study focuses on improving progression-free survival and overall outcomes for participants with advanced melanoma. Participants are assigned to one of three groups one group receives a low dose of brenetafusp once weekly for 13 weeks, then every two weeks until Week 51, and every four weeks thereafter, along with nivolumab every four weeks another group receives a high dose of brenetafusp on the same schedule plus nivolumab the third group receives nivolumab alone or nivolumab combined with relatlimab every four weeks. The study includes a dose recommendation phase with changes made in November 2025 based on safety and efficacy data. During the study, participants undergo assessments including tumor measurements per RECIST 1.1, BRAF V600 mutation status evaluation, and performance status scoring. Researchers will monitor progression-free survival up to approximately 45 months, overall survival up to 57 months, and record adverse events, immune responses, and quality of life. The study involves regular dosing and long-term follow-up to evaluate treatment effects and safety.
Actively Recruiting
Researchers are conducting a randomized, multicenter, multinational, double-blind Phase 3 study comparing MB11, a proposed nivolumab biosimilar, with EU- and US-sourced Opdivo in adults with previously untreated advanced unresectable or metastatic melanoma. The study aims to evaluate and compare the pharmacokinetics, efficacy, safety, and immune response of MB11 versus Opdivo as first-line treatment. Participants receive one of three study drugs MB11, EU-Opdivo, or US-Opdivo. During the first 12 treatment cycles, each is given as a 3 mgkg intravenous infusion over 30 minutes every two weeks. From Cycle 13 onwards, dosing continues either at 3 mgkg IV every two weeks or a flat dose of 240 mg IV every two weeks. The study treatment period covers at least 24 weeks for primary evaluation and up to 52 weeks for extended assessments. During the study, participants undergo regular assessments including tumor measurements by CT or MRI, biopsies for PD-L1 testing, and laboratory evaluations of organ function. Researchers monitor pharmacokinetics, efficacy, safety, and immunogenicity over the treatment period. Participants are followed through scheduled visits with evaluations up to one year, with continued safety monitoring and data collection until study completion in 2029.